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or many viral infections, resolution of illness is associ-
ated with long-term host control of viremia rather than
viral eradication. An example is EBV infection, and the
fact that host immune suppression is associated with
EBV-induced disease suggests that it is the immune system
that is holding the virus in check (1, 2). Other viruses are
typically associated with progressive uncontrolled disease,
and represent an expanding global problem. Over 30 mil-
lion persons are estimated to be infected with HIV-1 (3),
and HCV infection involves 4–6% of the population in
certain geographic regions of the world (4). Understanding
the correlates of immune protection against such progres-
sive viral infections and the development of effective vac-
cines thus has great urgency.
Data from both human studies and murine models sug-
gest that CTLs are an important host defense against vi-
ruses. CTLs recognize viral peptides that are processed
intracellularly and presented at the cell surface as a trimo-
 
lecular complex with 
 
b
 
2-microglobulin and HLA class I.
The fact that infected cells can be lysed before the produc-
tion of progeny virions is indicative of the potency of these
cells, at least under idealized laboratory conditions (5). In
addition to lysis, recognition of infected cells through the
epitope-specific TCR also leads to release of soluble anti-
viral factors (6). In HBV infection, both TNF-
 
a
 
 and IFN-
 
g
 
have been shown to lead to clearance of virus from infected
hepatocytes in a transgenic mouse model (7, 8). In HIV-1
infection, CTL activation by cognate epitope leads to se-
cretion of macrophage inflammatory protein (MIP)-1
 
a
 
,
MIP-1
 
b
 
, and RANTES (9, 10). These antiviral chemo-
kines are localized within cytotoxic granules as a complex
with sulfated proteoglycans, and are coordinately secreted
with granzymes and perforin, thus exposing the microen-
vironment of the infected cell with antiviral factors that
may serve to inhibit progeny that have already been pro-
duced (10).
The recent introduction of more sensitive quantitation
methods has provided increased evidence of the critical an-
tiviral role of CTLs (for review see reference 11). Direct
flow cytometric visualization of CTLs using tetrameric
complexes consisting of HLA class I, 
 
b
 
2-microglobulin,
and epitopic peptide shows that acute viral infections cause
massive CTL expansions that are associated with control
of viremia. In acute lymphocytic choriomeningitis virus
(LCMV) infection, tetramer staining has revealed that
 
.
 
50% of splenic CD8 cells may be LCMV specific (12),
and these high levels of CTLs have been confirmed using
functional assays for IFN-
 
g
 
 production by Elispot (12, 13).
Similar large expansions of CTLs have been observed in
acute human EBV infection where up to 44% of peripheral
blood CD8 cells are EBV-specific, class I–restricted CTLs
(14). Particularly important insights into the antiviral po-
tential of CTLs in the chronic phase of human viral in-
fection were recently provided by Ogg et al., who showed
a negative correlation between tetramer positive, HLA
A*0201-restricted CTLs, and control of HIV-1 viremia in
untreated infected patients (15).
The above studies demonstrate that CTLs are capable of
massive expansion in vivo and are associated with persistent
control of viremia. However, CTLs are clearly not effec-
tive in some viral infections. Chronic HIV-1 infection is
associated with progressive loss of CTLs (16, 17), and
chronic HCV infection is associated with low magnitude
CTL responses (18, 19). In both of these infections, viremia
is uncontrolled. It is thus important to determine what fac-
tors control the magnitude and persistence of CTLs, which
seem to be critical for efficient control of viremia. An im-
portant paper published in this issue by Zajac et al. (20)
confirms an essential role for virus-specific T helper cells in
maintaining CTL function, and provides new evidence that
CTL responses may be silenced in vivo, particularly in situ-
ations in which CD4 help is deficient.
The notion that CD4 T helper cells are critical for main-
tenance of CTLs and chronic control of viremia is not
new. The majority of published data come from murine
studies of specific strains of LCMV. Although not necessary
for the induction of primary CTL responses (21, 22), CD4
help is necessary for maintenance of CTL function during
the chronic phase of certain LCMV infections. In particu-
lar, under conditions of high dose infection or infection
with rapidly replicating and disseminating LCMV strains,
CD4 cells are required to prevent exhaustion of CTLs.
CD4 cells are not required to clear the less virulent Arm-
strong strain of virus, which is cleared by CTLs within
8–10 d in the presence or absence of CD4 cells (21, 23). The
situation is quite different for the more virulent LCMV
strains such as clone 13 and the macrophage-tropic LCMV
clone t1B. These viruses, which share 99.8% homology
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with the parental Armstrong strain, exhibit 10–50-fold en-
hanced replication, and even transient CD4 depletion at
the time of infection leads to complete loss of functional
CTLs and persistent viremia (23). Likewise, in CD4
knockout mice, infection with a high dose of the viscero-
lymphotropic LCMV strain WE leads to initial induction
of CTLs, but in the absence of CD4 help these CTLs dis-
appear, and chronic infection ensues (24). When CD4
 
2/2
 
mice are infected with the faster replicating LCMV strain
DOCILE, even low dose infection leads to abrogation of
virus-specific CTL responses and viral persistence (24). A
critical role for CD4 cells has also been shown after immu-
nization, in that immunization of mice deficient in CD4
cells leads to less efficient protection from subsequent viral
challenge (25). Progressive loss of CTLs in the absence of
adequate helper cell function has also been demonstrated
for murine 
 
g
 
-herpesvirus (26) and Friend virus infections
(27), and has been suggested to occur in humans after
adoptive transfer of CMV-specific CTLs (28). Although
these studies indicate a link between CD4 help and the
magnitude and persistence of CTLs, the mechanisms ac-
counting for this have been largely unclear.
New data presented by Zajac et al. (20) now provide in-
sights into how CD4 deficiency may impair CTL re-
sponses, and like other recent advances in understanding of
CTLs these data have been facilitated by the direct visual-
ization of CTL using peptide–MHC tetramers (29). A crit-
ical finding of this paper—which would have been missed
had tetramers not been available—is that antiviral CTLs can
persist in vivo in a nonfunctional state, and that this si-
lenced phenotype is more pronounced under conditions of
CD4 T cell deficiency. Moreover, epitope specificity and
antigen persistence appear to influence whether CTL re-
sponses are rendered persistent and nonfunctional or de-
leted.
Zajac et al. established chronic LCMV infections with
the rapidly replicating and widely disseminating LCMV
clones 13 and t1B in C57BL/6 mice, and compared these
to infections with the weaker Armstrong strain. CTL re-
sponses to the dominant class I–restricted envelope epitope
(GP33–41) and the nucleoprotein epitope (NP396–404)
were quantitated by stimulated CTL assays, limiting dilu-
tion precursor frequency assays, ELISPOT for cytokine
producing cells, and by direct visualization of epitope-spe-
cific CTLs with tetramers. As previously demonstrated,
LCMV infection with the less virulent Armstrong strain
was associated with viral clearance in CD4
 
1
 
/
 
1
 
 mice (22,
23). New analyses using MHC class I tetramers containing
epitopic peptides showed that immune mice chronically
maintained 
 
.
 
2% of CD8 cells specific for GP33 and 
 
.
 
5%
specific for NP396, and 100% of these cells maintained ef-
fector function as evidenced by IFN-
 
g
 
 production. The
outcome was similar in CD4
 
2/2
 
 mice infected with this less
virulent strain, which is consistent with previous studies
(24).
In CD4
 
1
 
/
 
1
 
 mice infected with the more rapidly replicat-
ing and widely disseminating LCMV clones 13 or t1b,
viremia was likewise cleared and persistent infection was
limited to the kidney. This immune control was associated
with strong CTL responses to the GP33 and NP396
epitopes, as evidenced by lysis of infected cells by CD8
cells, elaboration of IFN-
 
g
 
, and a high level of staining
with tetramers. However, tetramer analysis of the CD4
 
1
 
/
 
1
 
mice revealed a selective peripheral deletion of NP396-
specific CTLs, but maintenance of GP33-specific CTLs.
These cells appeared sufficient to control viremia, eliminat-
ing virus from most of the tissues. Only 10–20% of these
GP33-specific CTLs remained functional during the chronic
phase of infection, again as evidenced by lysis of infected
cells and production of IFN-
 
g
 
. Thus, in the presence of ad-
equate helper cell function, CTL responses to one epitope
were deleted in the early stages of infection, whereas CTL
responses to a second dominant epitope persisted, but a
large fraction were in a nonfunctional state.
The outcome of infection with the more virulent LCMV
strains in CD4
 
2/2
 
 mice was quite different. In these mice,
no functional CTLs could be detected in the chronic phase
of infection, and viremia was not controlled. However, tet-
ramer studies showed the initial induction of both GP33-
and NP396-specific CTLs, similar in number to those in-
duced in CD4
 
1
 
/
 
1
 
 mice, but these CTLs were unable to lyse
cells or produce IFN-
 
g
 
. Despite being nonfunctional, the
NP396-specific CTLs were peripherally deleted, with simi-
lar kinetics to that of CD4
 
1
 
/
 
1
 
 mice. In contrast, the tetra-
mer studies showed that the nonfunctional GP33-specific
CTLs persisted throughout the chronic phase of infection in
numbers comparable to those seen after infection of CD4
 
1
 
/
 
1
 
mice.
What is the explanation for the silenced phenotype of
these CTL? They are turning over in vivo as demonstrated
by BrdU labeling. Upregulation of CD69 in the majority
of GP33-specific cells indicated recent and continuous ex-
posure to antigen. However, only a small fraction of cells
(16%) were capable of eliciting IFN-
 
g
 
 after PMA stimula-
tion, and only a small fraction (15%) were turning over in
vivo despite high levels of circulating antigen. There are
parallels in the literature to describe T cells with hierarchi-
cal responses to different antigen concentrations. Levels of
TCR occupancy trigger different biological responses such
as cytotoxicity (where even a single peptide–MHC com-
plex may be sufficient to trigger a CTL response; reference
30), IFN-
 
g
 
 release, and IL-2 production (31, 32). The ab-
sence of appropriate costimulatory molecules can also
markedly increase the number of TCRs that need to be en-
gaged to trigger a T cell response to an agonist peptide (33,
34). Itoh and Germain found that clonal populations of
CD4 cells rendered anergic by an antagonist peptide had
cytokine profiles resembling those of cells exposed to low
levels of antigen or deprived of CD28 costimulation (35). It
is possible that sustained TCR signaling from high levels of
antigen in the absence of appropriate costimulation could
explain this functionally inactivated phenotype. Gallimore
et al. have observed a correlation between TCR downreg-
ulation on CTLs and prolonged contact with antigen, and
have shown that this correlates with decreased CTL activity
in the spleen of LCMV-infected mice (36). Their studies 
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also indicate that with high dose LCMV infection with the
WE strain, GP33-specific CTLs are induced, but only a
fraction of these make IFN-
 
g
 
, and are consistent with the
findings of Zajac et al. in showing that an anergic phase of
CTLs exists between CTL induction and depletion (36).
The nonfunctional CD8 responses were seen in the con-
text of rapidly replicating and widely disseminating LCMV
strains, suggesting that infection and dysfunction of APCs
may have been involved, preventing effector cells from re-
ceiving appropriate costimulation. Borrow et al. demon-
strated that interdigitating dendritic cells in the spleen are
infectable by LCMV clone 13 and are then targets for vi-
rus-specific CTLs (37). The recent work demonstrating
that activated CD4 cells are able to “condition” dendritic
cells through CD40–CD40L interactions raises the possibil-
ity that in the absence of sufficient helper activity dendritic
cells may not provide sufficient costimulatory signals to
CD8 cells, thus disrupting their normal functions (38–40).
Do these findings help to shed light on persistent uncon-
trolled human viral infections? The best studied chronic
human viral infection is HIV-1, and there are some striking
parallels with the LCMV model, both in terms of loss of
CTL function and deficiency of T helper cell responses.
Numerous studies have verified that progressive infection is
associated with loss of CTL responses (16, 17). Our own
data indicate that CTLs persist in progressive infection
but are incapable of in vivo expansion (Hay, C.M., D.J.
Ruhl, N.O. Basgoz, C.C. Wilson, J.M. Billingsley, M.P.
DePasquale, R.T. D’Aquila, and B.D. Walker, manuscript
submitted). This is certainly consistent with a lack of ade-
quate helper cell function. The most glaring defect in the
immune repertoire in HIV-1 infection is the lack of virus-
specific T helper cell responses. However, recent studies
show that HIV-1 is capable of inducing T helper cell re-
sponses, and that the magnitude of T helper cell responses
to the HIV-1 Gag protein are associated with control of
viremia in untreated persons (41). Particularly strong helper
responses are observed in persons who are spontaneously
maintaining extremely low viral loads and thus appear to be
successfully holding the virus in check, but these people are
rare. Individuals who successfully control HIV-1 in the ab-
sence of antiretroviral therapy also have strong and persis-
tent CTL responses (reference 42 and Kalams, S.A., S.P.
Buchbinder, J.M. Billingsley, E.S. Rosenberg, D.S. Col-
bert, N.G. Jones, A.K. Shea, A.K. Trocha, G.S. Ogg, P.J.
Goulder, and B.D. Walker, manuscript submitted).
Since HIV-1 infects activated CD4 cells and kills them
by a fas-dependent interaction (43), a possible mechanism
of depletion of virus-specific T helper cells is the infection
and elimination of these cells by HIV-1. Acute viral infec-
tions can induce large numbers of antigen-specific helper
cells, with the LCMV model showing that as many as 10%
of CD4 cells may be virus specific at the time of acute in-
fection (44). Such activated cells might be selectively in-
fected and eliminated in the earliest stages of acute HIV-1
infection. If this is true, then protection of activated cells by
potent antiviral therapy should prevent loss of these re-
sponses. In fact, aggressive treatment of persons with acute
HIV-1 infection has been associated with the detection of
Gag-specific T helper cells (41). In our own studies of
acutely infected persons treated before seroconversion,
control of viremia with potent combinations of antiviral
therapy including a protease inhibitor results in the predict-
able generation of strong HIV-1 Gag-specific T helper cell
responses, analogous to those seen in persons who are
spontaneously controlling viremia in the absence of antivi-
ral therapy (41). In contrast, such responses have not been
detected in persons treated in the chronic stage of infection
(45), which may be consistent with the findings of Zajac et
al., who find that even transient depletion of CD4 cells at
the onset of LCMV infection results in the life-long lack of
virus-specific CD4 cells.
Although treatment during acute HIV-1 infection results
in strong virus-specific T helper cells, whether these re-
sponses would contribute to effective control of viremia in
the absence of ongoing antiviral therapy has not been
tested. Other studies of treatment during acute AIDS virus
infections in animals suggest that the magnitude of early
viremia may have a profound influence on subsequent dis-
ease course. Watson et al. examined this issue in a patho-
genic HIV-2 infection model in macaques, in which ani-
mals were infected and then treated for just 16 wk with a
single nucleoside analogue, D4T. All control animals were
dead within 6 mo, as is expected in this model, but 5 out of
6 transiently treated animals remained alive and well with
control of viremia (46). Other studies of adoptive therapy
with neutralizing antibodies also show that lowering of vi-
ral load early on is associated with improved outcome (47).
Additional studies are needed to determine the immuno-
logic factors associated with improved outcome.
Another important finding by Zajac et al. is that the fate
of CTLs is epitope specific. This issue still needs further
testing in humans, which should be forthcoming as tetra-
mers to more HLA class I–restricted CTL epitopes are gen-
erated. The only published tetramer studies in HIV-1 in-
fection have concentrated on the CTL response to two
HLA A*0201–restricted CTL epitopes, one in the p17 Gag
protein (p17/77–85, SLYNTVATL), and the other in the
RT protein (RT 476–487, ILKEPVHGV). The tetramer
studies of HIV-1–infected subjects found that the percent-
age of tetramer-positive CD8
 
1
 
 T cells negatively correlated
with plasma viremia (15). Although the p17 Gag epitope is
more frequently recognized, the levels of RT epitope tet-
ramer-positive cells was also negatively correlated with
viral burden, and the combination of both tetramers
strengthened this negative correlation. The levels of direct
cell lysis are less than would be expected given the percent-
age of tetramer-positive cells, and perhaps this reflects per-
sistence of some nonfunctional cells as observed by Zajac et
al. for the GP33-specific CTL. Given reports that particular
HLA types are associated with more rapid disease progres-
sion (48, 49), it is possible that the tight correlation be-
tween HLA A*0201-Gag-specific CTL and viral load will
not be seen with all epitopes. The degree to which dif-
ferences in outcome may be related to silencing of spe-
cific CTL responses in vivo, and the relationship between 
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epitope density and functional inactivation, both require
further attention.
Several recent studies relating to murine control of viral
infections need to be examined in comparison to the report
by Zajac et al. A major question is whether other cells in
addition to CD4 and CD8 cells are critical to viral control.
Thomsen et al., examining class II–deficient (and therefore
lacking functional CD4 cells) mice, found that CTLs do
not persist. However, when similar experiments were per-
formed in mice lacking B cells due to a disruption in the
membrane exon of the 
 
m
 
 chain gene, CTL memory like-
wise could not be maintained and virus infection was not
contained. Antibody-producing B cells have also been
shown to be infected and deleted after LCMV infection
(50). After infection with low dose LCMV-WE, C57Bl/6
CD4 or B cell knockout mice are able to initially control
viral replication, but after 2 mo virus titers rise and CTL re-
sponses are exhausted. The control of viral replication can
only be restored after adoptive transfer of both CD4
 
1
 
 T
cells and B cells (51). These studies would suggest that ef-
fector cells are indeed unresponsive in the presence of high
levels of antigen, but also suggest that even a restoration of
help may not suffice to mediate control of viral replication.
Optimal effector function may exist (and persist) only in
the presence of optimal levels of APC function, CD4 help,
IFNs, and an appropriate initial antigen concentration. If
the phenotype of these impotent effector cells is an effect
and not the cause of high levels of antigen, then restoration
of help may not suffice to restore effector function in the
absence of a reduced viral burden. The answer to this ques-
tion is critical and has important implications for potential
immunotherapeutic interventions to prevent virologic re-
lapse in HIV-1–infected subjects on highly active antiretro-
viral therapy.
These studies provide strong evidence of yet another
way in which CTL control of viremia may be subverted in
chronic viral infections, namely by silencing of epitope-
specific CTL responses, and also show that CD4 T helper
cells play a critical role in determining the fate of effector
CTLs. It will be important to determine the relative con-
tribution of inactivated CTLs as a mechanism for persistent
viral infection in important human pathogens such as
HIV-1 and HCV. An important question to be answered is
whether some lack of detection of tetramer-positive cells
may be due to TCR downregulation. It will also be critical
to determine the precise mechanisms by which CD4 cells
contribute to CTL persistence, and whether silenced CD8
cells can be returned to functional competence. Identifica-
tion of methods to restore function to CTLs should be of
critical importance for immunotherapeutic strategies to
curtail persistent viral infections.
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